Business Segment Information

6 Months Ended

Sep. 30, 2012

Notes To Financial Statements [Abstract]

Business Segment Information

Business Segment Information

We operate and report in three business segments: Healthcare, Life Sciences, and Isomedix. Corporate and other, which is presented separately, contains the Defense and Industrial business unit plus costs that are associated with being a publicly traded company and certain other corporate costs.

Our Healthcare segment manufactures and sells capital equipment, accessory, consumable, and service solutions to healthcare providers, including acute care hospitals and surgery centers. These solutions aid our Customers in improving the safety, quality, and productivity of their surgical, sterile processing, gastrointestinal, and emergency environments.

Our Life Sciences segment manufactures and sells engineered capital equipment, formulated cleaning chemistries, and service solutions to pharmaceutical companies, and private and public research facilities around the globe.

Our Isomedix segment operates through a network of facilities located in North America. We sell a comprehensive array of contract sterilization services using gamma irradiation, and ethylene oxide (“EO”) technologies. We provide sterilization and microbial reduction services to companies that supply products to the healthcare, industrial, and consumer products industries.

Financial information for each of our segments is presented in the following table. Operating income (loss) for each segment is calculated as the segment’s gross profit less direct expenses and indirect cost allocations, which results in the full allocation of all distribution and research and development expenses, and the partial allocation of corporate costs. These allocations are based upon variables such as segment headcount and revenues. In addition, the Healthcare segment is responsible for the management of all but one manufacturing facility and uses standard cost to sell products to the Life Sciences segment. Corporate and other includes the gross profit and direct expenses of the Defense and Industrial business unit, as well as certain unallocated corporate costs related to being a publicly traded company and legacy pension and post-retirement benefits.

The accounting policies for reportable segments are the same as those for the consolidated Company. For the three and six month periods ended September 30, 2012, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2012, dated with the SEC on May 29, 2012.

Financial information for each of our segments is presented in the following tables:

	Three Months Ended September 30,						Six Months Ended September 30,
	2012			2011			2012			2011
Revenues:
Healthcare (1)	$	256,820		$	243,176		$	486,334		$	466,400
Life Sciences	54,577			58,915			115,073			111,783
Isomedix	44,284			39,999			90,340			82,002
Total reportable segments	355,681			342,090			691,747			660,185
Corporate and other	640			617			1,534			1,161
Total revenues	$	356,321		$	342,707		$	693,281		$	661,346
Operating income:
Healthcare (2)	$	42,147		$	27,994		$	64,877		$	54,262
Life Sciences	10,549			11,064			22,403			20,523
Isomedix	12,667			11,215			28,245			24,174
Total reportable segments	65,363			50,273			115,525			98,959
Corporate and other	(3,086		)	(2,630		)	(4,946		)	(4,415		)
Total operating income	$	62,277		$	47,643		$	110,579		$	94,544